Insulet Corporation (PODD) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Insulet Corporation · Health Care · ref. ETF XLV · 83 calls · price $143.41
What the company does: Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
📈 Insulet Corporation (PODD) stock price
$143.41-57.5% over range
Aug 28, 25low $133.26 · high $352.82Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
50% recommend buying · 20 analysts
📊 JPI status : Insulet Corporation has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 PODD price target & analyst consensus — price $143
The price target · all analysts combined (20 targets)
Highest target · 1 firm of 20$277+93.2%
Median target · of 20 targets$179+24.8%
Lowest target · 2 firms of 20$144+0.4%
Current price$143.41
Where these 20 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
20100%
$144 ↔ $277
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Deutsche Bank — 72% of its targets hit on this sector (291 calls tested). It aims for $190 (+33 %), call made on June 24, 2026, maturing on June 24, 2027 (65 d ago).
The 12 reliable analysts
$163+13 %
The 8 other firms
$209+46 %
How to read it: the 12 reliable firms are not filtered by optimism — 12 aim above the price, 0 below, hence their $163 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 20 ratings (last 6 months)
Strong Buy00%
Buy1050%
Hold945%
Sell15%
Strong Sell00%
Go deeper on the analysts
🎯 PODD price target all
All 19 calls, one by one, with our verdict on each firm.
→ See all 19 targets, analyst by analyst💡 The best analysts on PODD most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in PODD? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Insulet Corporation? The JPI assistant answers using our backtest data.
📈 Insulet Corporation fundamentals: valuation, margins & growth › open the full page
P/E 26.9Net margin 12.3 %Revenue growth +23.5 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 0 %
2023
Rev +30%Profit +4385%
2024
Rev +22%Profit +103%
2025
Rev +31%Profit −41%
🏛️ Insulet Corporation insider buying: who's buying and how much › open the full page
3 insiders bought3 buys / 6 mo $1.1M👥 Cluster buy
🔎 Detailed analyses
🏛️ Which US Congress members hold Insulet Corporation (PODD)?
1 Congress member has disclosed PODD buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Daniel Goldman 1× · 25%
✅ Historical analyst reliability on PODD
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| UBS ↗ | 100% | +63.5% | 3 |
| Feltl & Co. | 100% | +36.8% | 3 |
| BMO Capital ↗ | 100% | +29.5% | 3 |
| Morgan Stanley ↗ | 100% | +28.7% | 2 |
| Benchmark ↗ | 100% | +24.9% | 2 |
| BTIG ↗ | 89% | +48.0% | 9 |
| JP Morgan ↗ | 75% | +24.6% | 8 |
| Barclays ↗ | 75% | +21.7% | 4 |
| Canaccord Genuity ↗ | 71% | +26.9% | 14 |
| Jefferies ↗ | 67% | +30.0% | 9 |
See the other 13 firms
| RBC Capital ↗ | 0% | -28.8% | 2 |
| CFRA | 0% | -21.0% | 2 |
| TD Cowen ↗ | 33% | -13.6% | 3 |
| Wells Fargo ↗ | 40% | -7.9% | 5 |
| SVB Leerink | 43% | +9.2% | 7 |
| Wolfe Research ↗ | 50% | -5.2% | 2 |
| Oppenheimer ↗ | 50% | -4.2% | 4 |
| Northland Capital Markets ↗ | 50% | -3.2% | 2 |
| Cowen & Co. | 50% | -0.6% | 2 |
| Raymond James ↗ | 54% | +14.2% | 26 |
| Baird ↗ | 56% | +12.6% | 9 |
| Citigroup ↗ | 67% | +13.3% | 9 |
| Piper Sandler ↗ | 67% | +22.2% | 9 |
📊 What $1,000 invested in Insulet Corporation would be worth › open the full page
In short — $1,000 invested in Insulet Corporation 10 years ago would be worth $4,027 today, i.e. +15%/yr on average. Best year: 2019 (+116%), worst: 2023 (-26%). Price performance, excluding dividends.
If I'd invested $1,000 in Insulet Corporation
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $583 | -42% |
| 3 years ago | $517 | -48% |
| 5 years ago | $596 | -40% |
Return by year (Insulet Corporation)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -46% | $536 (-46%) |
| 2025 | +9% | $583 (-42%) |
| 2024 | +20% | $702 (-30%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Insulet Corporation
Loading news…
📋 All analyst calls on PODD
Filtered on — · ✕ show all
Canaccord Genuity ↗
Aug 7, 26
▲ Buy · 🎯$179
Price at call : $141.17 — upside +27%
Today : $143.41 — upside +25%
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
Leerink Partners ↗
Aug 6, 26
■ Market Perform neutral · not a buy · 🎯$145
Price at call : $141.17 — gap to target +3%
Today : $143.41 — gap to target +1%
🎯 on PODD : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
■ Hold neutral · not a buy · 🎯$144
Price at call : $141.17 — gap to target +2%
Today : $143.41 — gap to target +0%
🎯 on PODD : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
■ Neutral neutral · not a buy · 🎯$150
Price at call : $141.17 — gap to target +6%
Today : $143.41 — gap to target +5%
🎯 on PODD : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
RBC Capital ↗
Aug 6, 26
▲ Outperform · 🎯$160
Price at call : $141.17 — upside +13%
Today : $143.41 — upside +12%
🎯 on PODD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Outperform · 🎯$175
Price at call : $141.17 — upside +24%
Today : $143.41 — upside +22%
🎯 on PODD : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Buy · 🎯$185
Price at call : $141.17 — upside +31%
Today : $143.41 — upside +29%
🎯 on PODD : no call matured yet · 📊 on Health : 47.4% · -1.5% (19 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
▲ Buy · 🎯$180
Price at call : $141.17 — upside +28%
Today : $143.41 — upside +26%
🎯 on PODD : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
See the other 75 calls, newest to oldest
Wells Fargo ↗
Aug 6, 26
■ Equal-Weight neutral · not a buy · 🎯$144
Price at call : $139.3 — gap to target +3%
Today : $143.41 — gap to target +0%
🎯 on PODD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
■ Neutral neutral · not a buy · 🎯$152
Price at call : $139.3 — gap to target +9%
Today : $143.41 — gap to target +6%
🎯 on PODD : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
■ Neutral neutral · not a buy
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
Truist Securities ↗
Aug 6, 26
■ Hold neutral · not a buy · 🎯$153
Price at call : $139.3 — gap to target +10%
Today : $143.41 — gap to target +7%
🎯 on PODD : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
Truist Securities ↗
Jul 13, 26
▲ Buy · 🎯$210
Price at call : $159.12 — upside +32%
Today : $143.41 — upside +46%
🎯 on PODD : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
RBC Capital ↗
Jul 13, 26
▲ Outperform · 🎯$245
Price at call : $159.12 — upside +54%
Today : $143.41 — upside +71%
🎯 on PODD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
▲ Buy · 🎯$225
Price at call : $161.28 — upside +40%
Today : $143.41 — upside +57%
🎯 on PODD : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
■ Neutral neutral · not a buy · 🎯$172
Price at call : $158.29 — gap to target +9%
Today : $143.41 — gap to target +20%
🎯 on PODD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
Evercore ISI Group ↗
Jul 6, 26
▲ Outperform · 🎯$180
Price at call : $161.55 — upside +11%
Today : $143.41 — upside +26%
🎯 on PODD : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
Deutsche Bank ↗
Jun 23, 26
▲ Buy · 🎯$190
Price at call : $143.9 — upside +32%
Today : $143.41 — upside +32%
🎯 on PODD : no call matured yet · 📊 on Health : 53.3% · +4.5% (291 calls)
in progress (365j)
matures : Jun 23, 27
matures : Jun 23, 27
Truist Securities ↗
Jun 12, 26
▲ Buy · 🎯$219
Price at call : $148.14 — upside +48%
Today : $143.41 — upside +53%
🎯 on PODD : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jun 12, 27
matures : Jun 12, 27
■ Neutral neutral · not a buy · 🎯$165
Price at call : $144.94 — gap to target +14%
Today : $143.41 — gap to target +15%
🎯 on PODD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : May 28, 27
matures : May 28, 27
RBC Capital ↗
May 27, 26
▲ Outperform · 🎯$280
Price at call : $142.65 — upside +96%
Today : $143.41 — upside +95%
🎯 on PODD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 27, 27
matures : May 27, 27
▲ Buy · 🎯$235
Price at call : $146.01 — upside +61%
Today : $143.41 — upside +64%
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
in progress (365j)
matures : May 27, 27
matures : May 27, 27
B of A Securities ↗
May 18, 26
▲ Buy · 🎯$208
Price at call : $154.61 — upside +35%
Today : $143.41 — upside +45%
🎯 on PODD : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : May 18, 27
matures : May 18, 27
▼ Underweight · 🎯$198
Price at call : $154.17 — upside +28%
Today : $143.41 — upside +38%
🎯 on PODD : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 8, 27
matures : May 8, 27
Canaccord Genuity ↗
May 8, 26
▲ Buy · 🎯$249
Price at call : $154.16 — upside +62%
Today : $143.41 — upside +74%
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : May 8, 27
matures : May 8, 27
▲ Overweight · 🎯$275
Price at call : $154.16 — upside +78%
Today : $143.41 — upside +92%
🎯 on PODD : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
RBC Capital ↗
May 7, 26
▲ Outperform · 🎯$280
Price at call : $154.16 — upside +82%
Today : $143.41 — upside +95%
🎯 on PODD : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
Truist Securities ↗
May 7, 26
▲ Buy · 🎯$250
Price at call : $154.16 — upside +62%
Today : $143.41 — upside +74%
🎯 on PODD : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
Evercore ISI Group ↗
May 7, 26
▲ Outperform · 🎯$200
Price at call : $154.16 — upside +30%
Today : $143.41 — upside +39%
🎯 on PODD : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
Wells Fargo ↗
May 7, 26
▲ Overweight · 🎯$255
Price at call : $154.16 — upside +65%
Today : $143.41 — upside +78%
🎯 on PODD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
▲ Outperform · 🎯$200
Price at call : $160.4 — upside +25%
Today : $143.41 — upside +39%
🎯 on PODD : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
Oppenheimer ↗
May 7, 26
▲ Outperform · 🎯$210
Price at call : $160.4 — upside +31%
Today : $143.41 — upside +46%
🎯 on PODD : no call matured yet · 📊 on Health : 44.1% · +0.6% (220 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
■ Neutral neutral · not a buy · 🎯$175
Price at call : $160.4 — gap to target +9%
Today : $143.41 — gap to target +22%
🎯 on PODD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
▲ Buy · 🎯$260
Price at call : $160.4 — upside +62%
Today : $143.41 — upside +81%
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
Rothschild & Co
Apr 24, 26
■ Neutral neutral · not a buy · 🎯$220
Price at call : $189.56 — gap to target +16%
Today : $143.41 — gap to target +53%
🎯 on PODD : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Apr 24, 27
matures : Apr 24, 27
Truist Securities ↗
Apr 15, 26
▲ Buy · 🎯$315
Price at call : $201.47 — upside +56%
Today : $143.41 — upside +120%
🎯 on PODD : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Apr 15, 27
matures : Apr 15, 27
Goldman Sachs ↗
Apr 9, 26
▲ Buy · 🎯$277
Price at call : $196.93 — upside +41%
Today : $143.41 — upside +93%
🎯 on PODD : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Apr 9, 27
matures : Apr 9, 27
■ Neutral neutral · not a buy · 🎯$230
Price at call : $202.46 — gap to target +14%
Today : $143.41 — gap to target +60%
🎯 on PODD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Apr 7, 27
matures : Apr 7, 27
▲ Buy · 🎯$338
Price at call : $236.07 — upside +43%
Today : $143.41 — upside +136%
🎯 on PODD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Mar 11, 27
matures : Mar 11, 27
▲ Buy · 🎯$345
Price at call : $241.89 — upside +43%
Today : $143.41 — upside +141%
🎯 on PODD : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Truist Securities ↗
Feb 19, 26
▲ Buy · 🎯$360
Price at call : $241.89 — upside +49%
Today : $143.41 — upside +151%
🎯 on PODD : no call matured yet · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Goldman Sachs ↗
Feb 19, 26
▲ Buy · 🎯$326
Price at call : $241.89 — upside +35%
Today : $143.41 — upside +127%
🎯 on PODD : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
▲ Outperform · 🎯$330
Price at call : $241.89 — upside +36%
Today : $143.41 — upside +130%
🎯 on PODD : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Oppenheimer ↗
Feb 19, 26
▲ Outperform · 🎯$300
Price at call : $241.89 — upside +24%
Today : $143.41 — upside +109%
🎯 on PODD : no call matured yet · 📊 on Health : 44.1% · +0.6% (220 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
▲ Overweight · 🎯$340
Price at call : $241.89 — upside +41%
Today : $143.41 — upside +137%
🎯 on PODD : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Evercore ISI Group ↗
Feb 19, 26
▲ Outperform · 🎯$340
Price at call : $241.89 — upside +41%
Today : $143.41 — upside +137%
🎯 on PODD : no call matured yet · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Leerink Partners ↗
Feb 19, 26
▲ Outperform · 🎯$360
Price at call : $249.1 — upside +45%
Today : $143.41 — upside +151%
🎯 on PODD : no call matured yet · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
Canaccord Genuity ↗
Feb 19, 26
▲ Buy · 🎯$435
Price at call : $249.1 — upside +75%
Today : $143.41 — upside +203%
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
in progress (365j)
matures : Feb 19, 27
matures : Feb 19, 27
▲ Buy · 🎯$380
Price at call : $249.1 — upside +53%
Today : $143.41 — upside +165%
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
in progress (365j)
matures : Feb 18, 27
matures : Feb 18, 27
▲ Buy · 🎯$350
Price at call : $251.24 — upside +39%
Today : $143.41 — upside +144%
🎯 on PODD : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Feb 4, 27
matures : Feb 4, 27
Canaccord Genuity ↗
Aug 8, 25
▲ Buy · 🎯$353
Price at call : $304.84 — upside +16%
Today : $143.41 — upside +146%
Expected +16% · Actual -53% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-53.1%
stock -53% · XLV +29%
matured Aug 8, 26
Raymond James ↗
May 27, 25
▲ Outperform · 🎯$360
Price at call : $323.55 — upside +11%
Today : $143.41 — upside +151%
Expected +11% · Actual -56% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-55.9%
stock -56% · XLV +15%
matured May 27, 26
Raymond James ↗
Feb 21, 25
▲ Outperform · 🎯$328
Price at call : $283.48 — upside +16%
Today : $143.41 — upside +129%
Expected +16% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-12.0%
stock -12% · XLV +7%
matured Feb 21, 26
Canaccord Genuity ↗
Feb 21, 25
▲ Buy · 🎯$324
Price at call : $282.8 — upside +15%
Today : $143.41 — upside +126%
Expected +15% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-11.8%
stock -12% · XLV +8%
matured Feb 21, 26
Canaccord Genuity ↗
Dec 9, 24
▲ Buy · 🎯$304
Price at call : $274.79 — upside +11%
Today : $143.41 — upside +112%
Expected +11% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+7.4%
stock +7% · XLV +6%
matured Dec 9, 25
▲ Buy · 🎯$270
Price at call : $275.7 — upside -2%
Today : $143.41 — upside +88%
Expected -2% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+16.2%
stock +16% · XLV -1%
matured Nov 8, 25
Raymond James ↗
Oct 14, 24
▲ Outperform · 🎯$260
Price at call : $230.07 — upside +13%
Today : $143.41 — upside +81%
Expected +13% · Actual +36% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
+35.8%
stock +36% · XLV -7%
matured Oct 14, 25
▲ Buy · 🎯$260
Price at call : $230.07 — upside +13%
Today : $143.41 — upside +81%
Expected +13% · Actual +36% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+35.8%
stock +36% · XLV -7%
matured Oct 14, 25
Canaccord Genuity ↗
Sep 25, 24
▲ Buy · 🎯$269
Price at call : $235.43 — upside +14%
Today : $143.41 — upside +88%
Expected +14% · Actual +35% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+35.1%
stock +35% · XLV -12%
matured Sep 25, 25
▲ Buy · 🎯$250
Price at call : $188.05 — upside +33%
Today : $143.41 — upside +74%
Expected +33% · Actual +62% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+62.1%
stock +62% · XLV -13%
matured Aug 9, 25
Canaccord Genuity ↗
Jul 23, 24
▲ Buy · 🎯$234
Price at call : $196.76 — upside +19%
Today : $143.41 — upside +63%
Expected +19% · Actual +46% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+45.7%
stock +46% · XLV -8%
matured Jul 23, 25
Canaccord Genuity ↗
May 10, 24
▲ Buy · 🎯$234
Price at call : $161.02 — upside +45%
Today : $143.41 — upside +63%
Expected +45% · Actual +97% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+96.7%
stock +97% · XLV -5%
matured May 10, 25
Raymond James ↗
May 10, 24
▲ Outperform · 🎯$213
Price at call : $161.02 — upside +32%
Today : $143.41 — upside +49%
Expected +32% · Actual +97% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
+96.7%
stock +97% · XLV -5%
matured May 10, 25
Raymond James ↗
Sep 15, 23
▲ Outperform · 🎯$228
Price at call : $169.68 — upside +34%
Today : $143.41 — upside +59%
Expected +34% · Actual +38% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
+37.8%
stock +38% · XLV +19%
matured Sep 14, 24
Raymond James ↗
Aug 9, 23
▲ Outperform · 🎯$299
Price at call : $229.69 — upside +30%
Today : $143.41 — upside +108%
Expected +30% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-13.0%
stock -13% · XLV +11%
matured Aug 8, 24
Raymond James ↗
May 5, 23
▲ Outperform · 🎯$350
Price at call : $318.98 — upside +10%
Today : $143.41 — upside +144%
Expected +10% · Actual -45% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-44.7%
stock -45% · XLV +6%
matured May 4, 24
▲ Buy · 🎯$350
Price at call : $321.3 — upside +9%
Today : $143.41 — upside +144%
Expected +9% · Actual -48% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
-48.3%
stock -48% · XLV +4%
matured Apr 16, 24
Raymond James ↗
Feb 24, 23
▲ Outperform · 🎯$334
Price at call : $294.35 — upside +13%
Today : $143.41 — upside +133%
Expected +13% · Actual -43% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-42.6%
stock -43% · XLV +14%
matured Feb 24, 24
Raymond James ↗
Nov 4, 22
▲ Outperform · 🎯$320
Price at call : $313 — upside +2%
Today : $143.41 — upside +123%
Expected +2% · Actual -49% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-49.2%
stock -49% · XLV -2%
matured Nov 4, 23
Canaccord Genuity ↗
Aug 5, 22
▲ Buy · 🎯$290
Price at call : $263.06 — upside +10%
Today : $143.41 — upside +102%
Expected +10% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-0.8%
stock -1% · XLV +2%
matured Aug 5, 23
Raymond James ↗
Aug 5, 22
▲ Outperform · 🎯$280
Price at call : $267.05 — upside +5%
Today : $143.41 — upside +95%
Expected +5% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-2.3%
stock -2% · XLV +2%
matured Aug 5, 23
▲ Buy · 🎯$250
Price at call : $228.21 — upside +10%
Today : $143.41 — upside +74%
Expected +10% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+30.0%
stock +30% · XLV +1%
matured Jun 24, 23
Raymond James ↗
May 6, 22
▲ Outperform · 🎯$262
Price at call : $205.57 — upside +27%
Today : $143.41 — upside +83%
Expected +27% · Actual +55% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
+55.2%
stock +55% · XLV +3%
matured May 6, 23
Raymond James ↗
Feb 24, 22
▲ Outperform · 🎯$280
Price at call : $255.37 — upside +10%
Today : $143.41 — upside +95%
Expected +10% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 42% (12 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
+15.3%
stock +15% · XLV +1%
matured Feb 24, 23
▲ Buy · 🎯$320
Price at call : $243.49 — upside +31%
Today : $143.41 — upside +123%
Expected +31% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+20.0%
stock +20% · XLV -0%
matured Feb 3, 23
Canaccord Genuity ↗
Mar 19, 21
▲ Buy · 🎯$280
Price at call : $269.32 — upside +4%
Today : $143.41 — upside +95%
Expected +4% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
-5.9%
stock -6% · XLV +18%
matured Mar 19, 22
Canaccord Genuity ↗
Aug 6, 19
▲ Buy · 🎯$135
Price at call : $142.34 — upside -5%
Today : $143.41 — upside -6%
Expected -5% · Actual +55% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+54.9%
stock +55% · XLV +18%
matured Aug 5, 20
▲ Buy
Actual +98% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+97.5%
stock +98% · XLV +10%
matured May 5, 20
Canaccord Genuity ↗
May 23, 18
▲ Buy · 🎯$100
Price at call : $93.15 — upside +7%
Today : $143.41 — upside -30%
Expected +7% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+16.6%
stock +17% · XLV +8%
matured May 23, 19
Canaccord Genuity ↗
Nov 3, 17
▲ Buy
Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+20.7%
stock +21% · XLV +10%
matured Nov 3, 18
▲ Buy
Actual +120% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+120.4%
stock +120% · XLV +9%
matured May 10, 18
▲ Buy
Actual +98% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 89% (9 calls matureds) · 📊 on Health : 54.8% · +8.3% (115 calls)
+98.3%
stock +98% · XLV +22%
matured Nov 4, 17
Canaccord Genuity ↗
Jun 24, 13
▲ Buy · 🎯$37
Price at call : $30.99 — upside +19%
Today : $143.41 — upside -74%
Expected +19% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on PODD : 67% (12 calls matureds) · 📊 on Health : 53% · +6.1% (151 calls)
+23.1%
stock +23% · XLV +30%
matured Jun 24, 14
Frequently asked questions
Should I buy Insulet Corporation stock?
This isn't buy advice. For Insulet Corporation, the analyst consensus is "Hold", with an average price target of $179 (+25% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (3 calls tracked on Insulet Corporation). We show the numbers — you decide.
Is it too late to buy Insulet Corporation? How high can it go?
The most bullish analyst target on Insulet Corporation is $277 (+93% above today's price); the average is $179. That's the upside they see. Check how reliable those analysts have actually been on Insulet Corporation on our site before trusting it.
Is Insulet Corporation still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 23 analysts have a real record on Insulet Corporation, the best hitting 100% over 3 calls. Current consensus: "Hold". Make your call on data, not noise.
Will Insulet Corporation stock recover (go back up)?
It's down from its high. We answer with the numbers — the analysts' 12-month target and what happened after its past drops: will PODD stock recover (go back up)?
Should you invest in Insulet Corporation? The case for and against
The arguments for and against, one by one, from the numbers: why invest in PODD (and why hesitate).
What has Insulet Corporation's past performance been?
Historical returns and a "how much if I had invested" calculator: PODD performance & returns.
What is the best month to buy PODD?
The 12 months ranked by the stock's past returns: best & worst month to buy PODD.
Are insiders buying PODD stock?
Executives' and large holders' buys and sells, decoded: insider buying on PODD.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX